Company Profile
Hepion Pharmaceuticals Stock Price, News & Catalysts
- Ticker:
- HEPA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.12 USD (+20.00%)
Close
Last updated: October 6, 2026
—
Market cap
Why the stock is moving
As of Oct 6, 2026, HEPA closed up 20.0% at $0.1200. No new same-company headline was identified in the current news window.
Company overview
Medical Diagnostics Company
Hepion Pharmaceuticals has shifted from therapeutic drug development toward medical diagnostics. Its current strategy is based on licensed tests addressing infectious disease, gastrointestinal disease, and liver cancer.
Celiac and Infectious-Disease Testing
The licensed portfolio includes diagnostic tests for celiac disease and respiratory infections, including COVID-19, influenza A and B, and respiratory syncytial virus. These products are intended to support faster identification of clinically relevant conditions.
Gastrointestinal and Liver Diagnostics
Additional assets include tests for Helicobacter pylori and hepatocellular carcinoma. The liver-cancer program provides continuity with the company's historical expertise in chronic liver disease.
Cirna Diagnostics Relationship
Hepion licenses liver-disease diagnostic assets and related technology from Cirna Diagnostics. The model shifts the company away from funding large therapeutic trials and toward development, regulatory work, and commercialization of diagnostic products.
Legacy Rencofilstat Program
The company previously developed rencofilstat, a cyclophilin inhibitor for chronic liver diseases. That therapeutic program is no longer the center of its operating strategy but remains part of Hepion's scientific and corporate history.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Hepion Pharmaceuticals (HEPA)?
Hepion Pharmaceuticals (HEPA) most recently closed at 0.12 USD, a +20.00% move versus the previous session.
What does Hepion Pharmaceuticals do?
Medical Diagnostics Company Hepion Pharmaceuticals has shifted from therapeutic drug development toward medical diagnostics. Its current strategy is based on licensed tests addressing infectious disease, gastrointestinal disease, and liver cancer. Celiac and Infectious-Disease Testing The licensed portfolio includes diagnostic tests for celiac disease and...
On which exchange is HEPA stock listed?
Hepion Pharmaceuticals (HEPA) is associated with NASDAQ, United States, Biopharma.
What is COVID-19?
Celiac and Infectious-Disease Testing The licensed portfolio includes diagnostic tests for celiac disease and respiratory infections, including COVID-19, influenza A and B, and respiratory syncytial virus.
Which conditions is Hepion Pharmaceuticals targeting with COVID-19?
Hepion Pharmaceuticals is associated with cancer therapeutics, respiratory disease based on its company overview and current catalyst commentary.
What is rencofilstat?
Legacy Rencofilstat Program The company previously developed rencofilstat, a cyclophilin inhibitor for chronic liver diseases.
What is Medical?
Medical Diagnostics Company Hepion Pharmaceuticals has shifted from therapeutic drug development toward medical diagnostics.